In this multiple myeloma roundtable, the panelists contrast the distinct toxicity profiles of novel CELMoDs against established immunomodulatory agents to map out their role in long-term myeloma care.
The panel was moderated by Dr. Paul G. Richardson, clinical director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, who speaks with Dr. Meletios A. Dimopoulos, professor and chairman of the department of clinical therapeutics at the National and Kapodistrian University of Athens School of Medicine, Dr. Rahul Banerjee, assistant professor in the clinical research division at Fred Hutchinson Cancer Center, and Prof. Katja Weisel, deputy head of oncology, hematology and bone marrow transplantation at University Medical Center Hamburg-Eppendorf.
To ensure long-term clinical efficacy and treatment compliance, avoiding severe off-target side effects is vital to maintaining patient well-being, Prof. Weisel said.
“We got rid of off-target effects which are hampering life quality like fatigue, like GI toxicity,” she said. “So, I think it’s a regimen reflecting the needs of the patients.”
The favorable side-effect profile is especially critical during continuous maintenance therapy, where long-term drug adherence directly influences outcomes, Dr. Banerjee added to the discussion.
This video is being brought to you by an educational grant by Bristol Myers Squibb.
Leave feedback about this